A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury (SERENIA)
Latest Information Update: 21 Oct 2025
At a glance
- Drugs AZD 4144 (Primary)
- Indications Acute kidney injury
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms SERENIA
- Sponsors AstraZeneca
Most Recent Events
- 14 Oct 2025 New trial record